Several clinical studies reported that MAP/ERK kinase (MEK) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors, in combination with anti-PD1 therapy, generated long-lasting tumor control due to relative increases in IL-6 and IL-10 expression, and tumor susceptibility to T cell cytotoxic effects (168–170). This evidence concerns the gene BRAF and neoplasm.